Assessment of multistate disease progression is commonplace in biomedical research, such as in periodontal disease (PD). However, the presence of multistate current status endpoints, where only a single snapshot of each subject's progression through disease states is available at a random inspection time after a known starting state, complicates the inferential framework. In addition, these endpoints can be clustered, and spatially associated, where a group of proximally located teeth (within subjects) may experience similar PD status, compared to those distally located.
View Article and Find Full Text PDFRecent advances in sequencing technologies have allowed the collection of massive genome-wide information that substantially enhances the diagnosis and prognosis of head and neck cancer. Identifying predictive markers for survival time is crucial for devising prognostic systems and learning the underlying molecular drivers of the cancer course. In this paper, we introduce -KIDS, a model-free feature screening procedure with false discovery rate (FDR) control for ultrahigh-dimensional right-censored data, which is robust against unknown censoring mechanisms.
View Article and Find Full Text PDFBackground: Postmastectomy Radiotherapy (PMRT) has become standard of care for patients with breast cancer. However, local recurrence following breast conserving therapy is increasing in incidence due to increased survivorship. The relationship between prior radiation therapy, PMRT and immediate breast reconstruction (IBR) outcomes has not been widely studied.
View Article and Find Full Text PDFDeveloping protein-based drugs for oral administration is one of the most challenging aspects of research due to their low stability and inability to permeate through intestinal mucus barrier. Recent studies suggest that the ionic liquids (ILs) can combine with protein-based drugs to improve stability and mucus-penetration capabilities. However, the interactions among protein-based drugs, ILs, and mucin are rather unknown, which can play a pivotal role in such drug delivery.
View Article and Find Full Text PDFBackground: Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferase inhibitors (DNMTi) can augment immune responses to cancers, decreasing myeloid-derived suppressor cells (MDSCs) and increasing T lymphocyte responsiveness. We have shown that the DNMTi decitabine augments the effectiveness of immunotherapy using murine triple-negative breast cancer (TNBC) models.
View Article and Find Full Text PDFCancer Chemother Pharmacol
January 2025
Womens Health (Lond)
December 2024
Biosens Bioelectron
January 2025
J Indian Soc Probab Stat
May 2024
J Indian Soc Probab Stat
June 2024
ACS Biomater Sci Eng
May 2024
Stat Methods Med Res
March 2024